A look back through the nationwide Flatiron Health database reports fewer than 30% of patients undergoing resection for stage II-IIIA non-small cell lung cancer NSCLC received any form of neoadjuvant and/or adjuvant chemoimmunotherapy. | Desai, JAMA Netw Open 2025
